CEL383
Phase 1- Indications
- Inflammatory bowel disease
Company intelligence / Profile preview
Celsius Therapeutics
Cambridge, Massachusetts, United Statesabbvie.com ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Phase 1
01
Overview
Celsius Therapeutics advanced its lead candidate CEL383, an anti-TREM1 antibody, into a completed Phase 1 trial for IBD. The study evaluated safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers. No detailed results have been disclosed publicly as of the acquisition by AbbVie in June 2024.
- Therapeutic areas
- Gastroenterology
- Modalities
- Monoclonal antibodies (mAbs)Precision biologics (via single-cell genomics and machine learning)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ServierUniversity of OxfordCleveland ClinicLMU University Hospital Munich
Beyond the preview
Go deeper on Celsius Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celsius Therapeutics.